Search

ACADIA Pharmaceuticals Inc

Lezárt

SzektorEgészségügy

27.11 -0.95

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

26.64

Maximum

27.29

Fő mutatók

By Trading Economics

Bevétel

32M

35M

Értékesítés

40M

308M

P/E

Szektor átlag

12.341

56.432

Egy részvényre jutó nyereség

0.18

Profit margin

11.41

Munkavállalók

796

EBITDA

25M

32M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+29.82% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

356M

4.7B

Előző nyitás

28.06

Előző zárás

27.11

Hangulat hírek alapján

By Acuity

50%

50%

115 / 339 Rangsor szerint Healthcare

ACADIA Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 18. 22:46 UTC

ACADIA Pharmaceuticals Inc is down in after-market trading, following earlier losses, and remains below its 20-day moving average amid stagnant U.S. industrial production.

2026. szept. 17. 19:36 UTC

ACADIA Pharmaceuticals Inc shares fell sharply, pulling back from an early high and remaining 4.38% below its 20-day moving average.

2026. szept. 16. 19:16 UTC

ACADIA Pharmaceuticals Inc shares are higher, reaching a notable peak in early afternoon, despite trading below its 20-day moving average.

2026. szept. 14. 20:08 UTC

ACADIA Pharmaceuticals Inc shares are lower today, reflecting broader market declines amid rising crude oil prices and inflation concerns ahead of the Federal Reserve's decision.

2026. szept. 9. 20:07 UTC

ACADIA Pharmaceuticals Inc shares are higher Wednesday, pulling back earlier in the session. Broader market context includes rising crude oil prices above $100.

2026. szept. 8. 20:01 UTC

News

ACADIA Pharmaceuticals is lower today, driven by significant declines in the Biotechnology sub-sector, reversing recent higher closes since Friday.

2026. szept. 3. 20:02 UTC

Social Media

ACADIA Pharmaceuticals shares are declining, despite Canaccord Genuity and UBS reiterating Buy ratings and raising price targets amid positive outlooks for its products.

2026. szept. 2. 20:08 UTC

ACADIA Pharmaceuticals is higher today, driven by gains in biotechnology stocks. Earlier, the stock peaked above Tuesday's close before pulling back slightly.

2026. szept. 1. 20:09 UTC

ACADIA Pharmaceuticals is lower in Tuesday trading, in line with broader market declines amid rising oil prices and increasing Treasury yields.

2026. aug. 31. 21:01 UTC

ACADIA Pharmaceuticals is higher in after-market trading, reflecting a notable move since Monday's close amid broader market sentiment on potential interest rate hikes.

2026. aug. 28. 20:07 UTC

News

ACADIA Pharmaceuticals received EU approval for DAYBU to treat Rett syndrome. Shares are declining despite this development, reflecting unusual volatility during Friday's session.

2026. aug. 27. 23:41 UTC

ACADIA Pharmaceuticals shares are trading lower in after-market hours, despite being above the 20-day moving average and near the upper end of its trading range.

2026. aug. 26. 20:08 UTC

ACADIA Pharmaceuticals is trading lower amid a weaker market following inflation data that may influence future Federal Reserve policy decisions.

2026. aug. 25. 20:07 UTC

News
Event

Analysts' upgrades boost ACADIA Pharmaceuticals, with Deutsche Bank raising its price target to $38 and Citigroup to $40 following DAYBUE's EU approval.

2026. aug. 24. 20:06 UTC

News
Event

ACADIA Pharmaceuticals received European Commission approval for DAYBU, the first treatment for Rett syndrome in the EU. Shares are advancing during Monday's session.

2026. aug. 21. 19:56 UTC

ACADIA Pharmaceuticals shares are higher, recovering from an early dip. The move aligns with broader market trends following a surge in Bitcoin prices.

2026. aug. 20. 20:01 UTC

ACADIA Pharmaceuticals shares are lower amid a broader decline in biotechnology stocks, with unusual volatility noted today and cumulative returns down since Wednesday.

2026. aug. 19. 19:46 UTC

ACADIA Pharmaceuticals is trading higher, reflecting positive sentiment in the biotechnology sector amid declining bond yields and increased liquidity, despite a recent pullback.

2026. aug. 18. 20:02 UTC

News

BMO maintained an Outperform rating on ACADIA Pharmaceuticals with a $36 price target, contributing to positive market sentiment and advancing shares today.

2026. aug. 17. 23:06 UTC

ACADIA Pharmaceuticals shares are trading higher in after-market hours, maintaining a gain while above their 20-day moving average and near a one-month high.

2026. aug. 13. 20:01 UTC

ACADIA Pharmaceuticals Inc shares are lower today, continuing a decline from Wednesday's close. No specific news was identified to explain the movement.

2026. aug. 12. 19:56 UTC

News

Needham maintained its Buy rating on ACADIA Pharmaceuticals and raised the price target to $41. Shares are trading higher since Tuesday's close.

2026. aug. 11. 19:36 UTC

ACADIA Pharmaceuticals remains near unchanged amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports affecting interest rate policy.

2026. aug. 7. 20:06 UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

2026. aug. 6. 23:41 UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

2026. aug. 5. 20:02 UTC

News

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

2026. aug. 4. 23:01 UTC

News

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

2026. aug. 3. 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

2026. júl. 31. 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

2026. júl. 30. 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

Társak összehasonlítása

Árváltozás

ACADIA Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

29.82% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 35.429 USD  29.82%

Magas 49 USD

Alacsony 25 USD

15 Wall Street elemző 12 hónapos célárain alapulva a(z)ACADIA Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

15 ratings

11

Vétel

4

Tartás

0

Eladás

Hangulat

By Acuity

115 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.